Pharmakon Advisors, LP (New York)

Name: Pharmakon Advisors, LP
Address: 110 East 59 Th Street, New York, NY, 10022 1304
Telephone: 212-883-2296

Pharmakon Advisors, LP is a large advisory firm based in New York. It manages $1.91 billion of regulatory assets for 11 client accounts. It has been registered with the SEC as an adviser since 2012 and has operated in the jurisdiction of New York.

Pharmakon Advisors provides portfolio management for pooled investment vehicles, portfolio management for businesses and institutional clients, and portfolio management for endowments. It doesn't provide financial planning services to its clients. On top of advisory services, the firm doesn't engage in other business activities.

Pharmakon Advisors: assets under management

The assets under management (AUM) of Pharmakon Advisors, LP is $1.91 billion. The firm's AUM has grown by 294% since the beginning of its operation, and $1.85 billion of the total AUM is attributable to clients outside of the United States.

The firm manages $1.76 billion in discretionary accounts and $144.94 million in non-discretionary accounts. On average, the discretionary accounts where all decisions are made on behalf of the client hold $293.52 million each. Non-discretionary accounts, where clients actively manage their portfolios, generally hold around $28.99 million.

Pharmakon Advisors has custody of $693.18 million in cash and securities for 6 clients in total but doesn’t act as a qualified custodian.

Investments

The firm invests in other assets the most. They account for 100% of the total AUM.

Fees & Commissions

The advisory firm has several streams of revenue. Clients pay Pharmakon Advisors, LP for their services and products based on a percentage of assets under management and performance-based fees. The adviser charges an additional fee when a set benchmark is outperformed. These fees don’t include brokerage commissions, interest, taxes, and other account expenses.

What kind of clients Pharmakon Advisors serves?

The only and largest group of clients of Pharmakon Advisors is pooled investment vehicles with 5 clients and $367.85 million of assets under management. Among the 11 most similar advisory firms, Pharmakon Advisors has the 4th lowest percentage of pooled investment vehicles out of all clients.

The amount of regulatory assets under management is $367.85 million for 5 clients. 82% of the firm’s clients are foreign persons or businesses.

Pharmakon Advisors also advises several private funds. Namely, five private equity funds.

Careers at Pharmakon Advisors, LP

The company employs 7 people that are either part- or full-time employees. 57 percent of the employees work as investment advisers or researchers. No employees are registered as investment adviser representatives with the state securities authorities.

There isn’t anyone with the role of looking for and bringing in new clients on behalf of the firm. The firm doesn’t compensate employees in addition to the salary for bringing in new clients. Employees don’t receive compensation from other entities for client referrals.

Direct owners and executive officers

Name	Entity	Date acquired	Ownership	Employer ID
Pedro Gonzalezdecosio	Chief compliance officer, chief executive officer	1 Apr 2009	25% - 50%	2364692
Pablo Gerardo Legorreta	Managing member	1 Apr 2009	25% - 50%	2550243
Benjamin Claas Schliemann	Managing member	1 Apr 2009	25% - 50%	5055233
Pharmakon Management I Llc	Owner	1 Apr 2010	Other	00-0000000
Martin G Friedman	Managing member	1 Jan 2013	25% - 50%	2632022
Martin Gershon Friedman	Managing member of gp	1 Jan 2013	25% - 50%	2632022

Based in New York

The principal office where Pharmakon Advisors, LP performs its advisory services is located at 110 East 59 Th Street, New York, NY 10022 1304, which is also the mailing address of the firm. It doesn’t run an office outside of the United States.

You can reach the main office by calling the phone number 212-883-2296 or by fax 917-210-4048. The normal business hours are 9:00 am - 6:00 pm on Monday - Friday. You can find more information about the New York firm at biopharmafunds.com/.